BioSpace News Archive

The Institute for Research in Immunology and Cancer of the Université de Montréal is proud to announce that David Knapp and Geneviève Deblois have been recruited as new Principal Investigators.

Rakuten Medical, Inc. (Rakuten Medical) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical’s proprietary Illuminox ™ technology platform.

Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today expanded a collaborative partnering effort for its lead product candidate tecarfarin. Tecarfarin is a Phase III-ready, vitamin K antagonist, taken once

Dr. Majid Fotuhi, MD, PhD, a nationally-recognized neurologist, is warning about neurological issues in patients who suffer from COVID-19

AmorChem is proud to announce a new investment in a research program hailing from Université Laval and the Research Center of the Centre Hospitalier Universitaire de Québec. The venture capital fund identified the opportunity in close collaboration with SOVAR, a group active in the promotion of university research. Am

Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that it will be participating in the upcoming BIO Digital International Convention. Details: Event: BIO Digital 2020 Date: J

Amplifon Hearing Health Care, a leading player in hearing benefit solutions, has earned accreditation from the National Committee for Quality Assurance for the credentialing and recredentialing of hearing health care providers in the Amplifon network.

Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, located in Hyderabad India , recently received FDA approval for their generic versions of Oseltamivir Phosphate Capsules and Dofetilide Capsules.

Elixirgen Therapeutics, Inc., a Baltimore -based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, announced that it concluded on May 18 its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the company’s C

FSD Pharma Inc. (NASDAQ: HUGE) (“FSD Pharma” or the “Company”), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share pursuant to a private placement resulting in gross proceeds of approximately C$10.125 million. The Company has also agreed to issue com